Donna Niedzwiecki

Donna Niedzwiecki

UNVERIFIED PROFILE

Are you Donna Niedzwiecki?   Register this Author

Register author
Donna Niedzwiecki

Donna Niedzwiecki

Publications by authors named "Donna Niedzwiecki"

Are you Donna Niedzwiecki?   Register this Author

100Publications

2405Reads

36Profile Views

Reply to S. Sorscher.

J Clin Oncol 2019 Sep 3;37(25):2291-2293. Epub 2019 Jul 3.

Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01366DOI Listing
September 2019

Predictors of Clinical Outcome After Treatment of Intracranial Aneurysms with the Pipeline Embolization Device.

World Neurosurg 2019 Jul 2. Epub 2019 Jul 2.

Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.06.185DOI Listing
July 2019

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Cancer Chemother Pharmacol 2019 Jun 20;83(6):1025-1035. Epub 2019 Mar 20.

Duke University Medical Center, Seeley G. Mudd Bldg 10 Bryan Searle Drive, Box 3505, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03805-6DOI Listing
June 2019

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Eur J Cancer 2019 Apr 1;111:82-93. Epub 2019 Mar 1.

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.01.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436990PMC
April 2019

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Contemp Clin Trials 2018 09 10;72:73-85. Epub 2018 Jul 10.

Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, DUMC 3913, Durham, NC 27710, USA; Duke Clinical Research Institute, 2400 Pratt Street, Rm. 0311, Terrace Level, Durham, NC 27705, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2018.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711183PMC
September 2018

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

J Clin Oncol 2018 04 28;36(11):1112-1120. Epub 2018 Feb 28.

Temidayo Fadelu, Sui Zhang, Robert J. Mayer, Shuji Ogino, Kimmie Ng, Jeffrey Meyerhardt, and Charles S. Fuchs, Dana-Farber/Partners CancerCare; Shuji Ogino, Kana Wu, Walter Willett, and Edward Giovannucci, Harvard TH Chan School of Public Health; Shuji Ogino, Edward Giovannucci, and Ying Bao, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University, Durham; Michael Messino, Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al B. Benson, Robert H Lurie Comprehensive Cancer Center, Northwestern University; Hedy L. Kindler, University of Chicago Comprehensive Cancer, Chicago, IL; Daniel M. Atienza, Virginia Oncology Associates, Norfolk, VA; Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA; and Charles S. Fuchs, Yale Cancer Center, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891130PMC
April 2018

Reply to L. Fornaro et al.

J Clin Oncol 2018 04 28;36(11):1179-1180. Epub 2018 Feb 28.

Charles S. Fuchs, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT; and Donna Niedzwiecki, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.1030DOI Listing
April 2018

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

N Engl J Med 2018 Mar;378(13):1177-1188

From the Divisions of Medical Oncology (A.G.) and Biomedical Statistics and Informatics (Q.S., J.P.M., L.A.R., D.J.S.), Mayo Clinic, Rochester, MN; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino-IST, Genoa (A.F. Sobrero), Ospedale Papa Giovanni XXIII, Bergamo (R.L.), and IRCCS Mario Negri Institute for Pharmacological Research, Milan (V.T.) - all in Italy; Karmanos Cancer Institute, Wayne State University, Detroit (A.F. Shields); National Cancer Center Hospital East, Chiba (T. Yoshino), Yokohama City University School of Medicine, Yokohama (T. Yamanaka), and the University of Tokyo, Tokyo (T.W.) - all in Japan; the Institute of Cancer Sciences, University of Glasgow, Glasgow (J.P.), the University of Oxford, Oxford (R.K.), Christie Hospital, Manchester (M.S.), and University Hospital Southampton, Southampton (T.I.) - all in the United Kingdom; Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University (J.T.), and Saint-Antoine Hospital and Sorbonne Universités, Pierre and Marie Curie University-Paris 6 (T.A.), Paris, and Methodology and Quality of Life Unit, INSERM Unité 1098, Besançon (D.V.) - all in France; the Department of Medical Oncology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion (J.S.), and Bioclinic Thessaloniki, Thessaloniki (I.B.) - both in Greece; Dana-Farber Cancer Institute, Boston (J.A.M.); and Duke Cancer Institute, Durham, NC (D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426127PMC
March 2018

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J Clin Oncol 2017 Nov 4;35(32):3671-3677. Epub 2017 Oct 4.

Charles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.2130
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.2130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342PMC
November 2017

Socioeconomic Status, Not Race, Is Associated With Reduced Survival in Esophagectomy Patients.

Ann Thorac Surg 2017 Jul 12;104(1):234-244. Epub 2017 Apr 12.

Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2017.01.049DOI Listing
July 2017

Reply to L. Casadaban et al.

J Clin Oncol 2017 04 23;35(12):1373-1374. Epub 2017 Jan 23.

Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.2646
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.2646DOI Listing
April 2017

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Cancer Chemother Pharmacol 2017 03 25;79(3):611-619. Epub 2017 Feb 25.

Duke Cancer Institute, Duke University Medical Center, Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3256-2DOI Listing
March 2017

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

J Clin Oncol 2016 09 18;34(25):3047-53. Epub 2016 Jul 18.

Donna Niedzwiecki and Xing Ye, Duke University, Durham; Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC; Wendy L. Frankel and Richard M. Goldberg, The Ohio State University, Columbus, OH; Alan P. Venook and Robert S. Warren, University of California-San Francisco, San Francisco, CA; Paula N. Friedman, The University of Chicago, Chicago, IL; Robert J. Mayer, Dana-Farber Cancer Institute; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Thomas Anthony Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Richard D. Kennedy, and D. Paul Harkin, Almac Diagnostics, Craigavon; Patrick G. Johnston, Queen's University, Belfast, Northern Ireland; and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.4699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012711PMC
September 2016

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

J Clin Oncol 2016 08 5;34(23):2736-42. Epub 2016 Jul 5.

Peter C. Enzinger and Robert J. Mayer, Dana-Farber Cancer Institute, Harvard Medical School, and Alliance for Clinical Trials in Oncology, Boston, MA; Barbara Ann Burtness and Steven J. Cohen, Fox Chase Cancer Center; Barbara Ann Burtness, Steven J. Cohen, and Al Bowen Benson III, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Philadelphia, PA; Donna Niedzwiecki, Xing Ye, and Kathe Douglas, Alliance Statistics and Data Center, Duke University, Durham, NC; David H. Ilson, Memorial Sloan Kettering Cancer Center and Alliance for Clinical Trials in Oncology, New York, NY; Victoria Meucci Villaflor, University of Chicago Medicine and Alliance for Clinical Trials in Oncology; Al Bowen Benson III, Northwestern University Feinberg School of Medicine, Chicago, IL; Alan Venook, University of California San Francisco Helen Diller Family Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, San Francisco, CA; and Richard M. Goldberg, Ohio State University James Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, Columbus, OH.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/06/30/JCO.2015.65
Web Search
http://dx.doi.org/10.1200/JCO.2015.65.5092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019745PMC
August 2016

Big Data, Small Effects.

J Clin Oncol 2016 Apr 16;34(11):1170-1. Epub 2016 Feb 16.

Duke University School of Medicine, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8161DOI Listing
April 2016

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

J Clin Oncol 2015 Nov 17;33(31):3598-607. Epub 2015 Aug 17.

Brendan J. Guercio, Shuji Ogino, and Edward L. Giovannucci, Harvard Medical School; Kaori Sato, Robert J. Mayer, Shuji Ogino, Jeffrey A. Meyerhardt, and Charles S. Fuchs, Dana-Farber Cancer Institute; Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, and Edward L. Giovannucci, Harvard T.H. Chan School of Public Health; Shuji Ogino and Edward L. Giovannucci, Brigham and Women's Hospital, Boston, MA; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al Benson, Northwestern University; Hedy Kindler, University of Chicago, Chicago, IL; Daniel Atienza, Virginia Oncology Associates, Norfolk, VA; Donna Niedzwiecki and Xing Ye, Duke University Medical Center, Durham; Michael Messino, Southeast Cancer Control Consortium, Mission Hospitals, Asheville, NC; and Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.5062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622099PMC
November 2015

MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

PLoS One 2014 13;9(10):e108483. Epub 2014 Oct 13.

Department of Immunology, University of Washington, Seattle, Washington, United States of America; Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, Washington, United States of America; Department of Pathology, University of Washington Medical School, Seattle, Washington, United States of America; Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108483PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195600PMC
June 2015

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.

Support Care Cancer 2015 May 24;23(5):1311-9. Epub 2014 Oct 24.

Duke Cancer Institute, Seeley G. Mudd Bldg., 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-014-2465-z
Publisher Site
http://dx.doi.org/10.1007/s00520-014-2465-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973630PMC
May 2015

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

J Natl Cancer Inst 2015 Jan 27;107(1):345. Epub 2014 Nov 27.

: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (KN, JAM, KS, JAC, RJM, SO, CSF); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA (ATC, ELG, CSF); Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC (DN); Memorial Sloan-Kettering Cancer Center, New York, NY (LBS); Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL (ABB); Toledo Community Hospital Oncology Program, Toledo, OH (PLS); Hopital du Sacre-Coeur de Montreal, Universite de Montreal, Quebec, Canada (RW); Edward Cancer Center, Naperville, IL (AH); Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG); Division of Medical Oncology, University of California at San Francisco, San Francisco, CA (APV); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology (SO, ELG) and Department of Nutrition (ELG), Harvard School of Public Health, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271076PMC
January 2015

25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).

J Natl Cancer Inst 2014 Aug 6;106(8). Epub 2014 Aug 6.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA (KVL, APV); Department of Biostatistics and Bioinformatics, Duke University, Durham, NC (KO, DN); Alliance Statistics and Data Center, Duke University, Durham, NC (KO, CJ, DN); The University of Chicago Medical Center, Chicago, IL (HLK); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL (MFM); Memorial Sloan-Kettering Cancer Center, New York, NY (EMO); Dana-Farber Cancer Institute, Boston, MA (CF); University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC (FI).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155431PMC
August 2014

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Ann Surg 2013 Dec;258(6):879-86

Departments of *Medicine, †Biostatistics and Bioinformatics, ‡Surgery, Duke University Medical Center §Duke Comprehensive Cancer Center, ‖Department of Immunology, Duke University Medical Center, Durham, NC ¶Georgetown University, Washington, DC **MD Anderson Cancer Center, Houston, TX ††Wake Forest University Baptist Medical Center, Winston-Salem, NC ‡‡Earle Chiles Cancer Center, Providence Portland Medical Center, Portland, OR §§Medical University of South Carolina, Charleston, SC ‖‖Moffitt Cancer Center, Tampa, FL. Dr Chang is now with Virginia Oncology Associates, Newport News, VA. Dr Clay is now with GlaxoSmithKline, Rixensart, Belgium.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/SLA.0b013e318292919eDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812363PMC
December 2013

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

J Natl Cancer Inst 2013 Dec 14;105(23):1789-98. Epub 2013 Nov 14.

Affiliations of authors: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF); Department of Pathology (SO), Channing Division of Network Medicine, Department of Medicine (DS, CSF), and Department of Surgery (MMB), Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology (SO, DS) and Department of Biostatistics (DS) , Harvard School of Public Health, Boston, MA; Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC (DN); Memorial Sloan-Kettering Cancer Center, New York, NY (LBS); Hôpital du Sacré-Coeur de Montréal, Montreal, Canada (RW); Loyola University Stritch School of Medicine, Maywood, IL (AH); current: Edward Cancer Center, Naperville, IL (AH); Northwestern University, Chicago, IL (ABB); Toledo Community Hospital Oncology Program, Toledo, OH (RBM); Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH (RMG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848984PMC
December 2013

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Clin Cancer Res 2013 Oct 27;19(20):5777-87. Epub 2013 Aug 27.

Authors' Affiliations: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; Department of Biostatistics and Bioinformatics, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; Dana-Farber Cancer Institute; Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts; The Ohio State University, Columbus, Ohio; National Cancer Institute, Bethesda, Maryland; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122229PMC
October 2013

Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.

Clin Colorectal Cancer 2013 Jun 12;12(2):95-102. Epub 2013 Jan 12.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2012.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790266PMC
June 2013

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).

J Transl Med 2012 Dec 10;10:246. Epub 2012 Dec 10.

The University of Chicago, Section of Hematology/Oncology, 5841 S, Maryland Ave, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-10-246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543225PMC
December 2012

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Biol Blood Marrow Transplant 2011 Jun 22;17(6):867-74. Epub 2010 Sep 22.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877679PMC
June 2011

Long-term follow-up of survival in Hodgkin's lymphoma.

N Engl J Med 2009 Dec;361(24):2390-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc0906731DOI Listing
December 2009

Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.

J Gastrointest Surg 2009 Jan 7;13(1):74-84. Epub 2008 Aug 7.

Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-008-0617-5DOI Listing
January 2009

Immune reconstitution in children after unrelated cord blood transplantation.

Biol Blood Marrow Transplant 2008 Jan;14(1 Suppl 1):66-72

Department of Pediatrics, Pediatric Blood and Marrow Transplant Program, Department of Immunology, Duke University, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2007.10.016DOI Listing
January 2008

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Leuk Lymphoma 2007 Jul;48(7):1313-9

Division of Hematology - Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190701411458DOI Listing
July 2007

The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Gastroenterology 2007 Jan 20;132(1):127-38. Epub 2006 Sep 20.

Division of Gastroenterology, Department of Internal Medicine and Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2006.09.018DOI Listing
January 2007

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

Cancer 2006 Dec;107(12):2817-25

Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22344DOI Listing
December 2006

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

Cancer 2006 Oct;107(8):1883-90

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22239DOI Listing
October 2006